Video

Reviewing Data in Frontline Metastatic RCC Treatment from the COSMIC-313 Trial

Drs Moshe Ornstein and Hans Hammers review data from the COSMIC-313 trial investigating ipilimumab, nivolumab, and cabozantinib for the frontline treatment of metastatic renal cell carcinoma.

Related Videos
Charles B. Nguyen, MD
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Yousef Zakharia, MD
Nazli Dizman, MD
Adam E. Singer, MD, PhD, health sciences clinical instructor, medicine, division lead, Kidney Cancer, Division of Hematology/Oncology, UCLA Health
Bradley McGregor, MD,
David A. Braun, MD, PhD
David A. Braun, MD, PhD
Bradley McGregor, MD,
Ami Umesh Badami, MD, medical oncologist, Endeavor Health Medical Group